Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion

[1]  Aviv Regev,et al.  Cumulus provides cloud-based data analysis for large-scale single-cell and single-nucleus RNA-seq , 2020, Nature Methods.

[2]  K. Rudolph,et al.  Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma , 2020, Nature Communications.

[3]  C. Evans,et al.  Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis , 2020, Frontiers in Immunology.

[4]  Michael I. Jordan,et al.  Deep Generative Models for Detecting Differential Expression in Single Cells , 2019, bioRxiv.

[5]  S. Agrawal,et al.  Intratumoural immunotherapy: activation of nucleic acid sensing pattern recognition receptors , 2019, Immuno-oncology technology.

[6]  Neville E. Sanjana,et al.  Multiplexed detection of proteins, transcriptomes, clonotypes and CRISPR perturbations in single cells , 2019, Nature Methods.

[7]  Aaron M. Newman,et al.  A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPα expression , 2019, Nature Communications.

[8]  Monika S. Kowalczyk,et al.  A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade , 2018, Cell.

[9]  K. Brown,et al.  Tumor immune evasion arises through loss of TNF sensitivity , 2018, Science Immunology.

[10]  A. Veillette,et al.  SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy. , 2018, Trends in immunology.

[11]  J. Wargo,et al.  The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression , 2018, Clinical Cancer Research.

[12]  Henry W. Long,et al.  A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing , 2018, Science.

[13]  Fabian J Theis,et al.  SCANPY: large-scale single-cell gene expression data analysis , 2018, Genome Biology.

[14]  R. Davis,et al.  The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy , 2017, Journal of the National Cancer Institute.

[15]  Nir Hacohen,et al.  Resistance to checkpoint blockade therapy through inactivation of antigen presentation , 2017, Nature Communications.

[16]  R. Davis,et al.  HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes , 2017, Nature Communications.

[17]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[18]  John G. Doench,et al.  In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target , 2017, Nature.

[19]  H. Swerdlow,et al.  Large-scale simultaneous measurement of epitopes and transcriptomes in single cells , 2017, Nature Methods.

[20]  I. Amit,et al.  Dissecting Immune Circuits by Linking CRISPR-Pooled Screens with Single-Cell RNA-Seq , 2016, Cell.

[21]  Thomas M. Norman,et al.  A Multiplexed Single-Cell CRISPR Screening Platform Enables Systematic Dissection of the Unfolded Protein Response , 2016, Cell.

[22]  Thomas M. Norman,et al.  Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens , 2016, Cell.

[23]  André F. Rendeiro,et al.  Pooled CRISPR screening with single-cell transcriptome read-out , 2017, Nature Methods.

[24]  J. Wargo,et al.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy , 2016, Cell.

[25]  Zhijian J. Chen,et al.  Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing , 2016, Nature Immunology.

[26]  T. Graeber,et al.  Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.

[27]  J. McQuade,et al.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. , 2016, Cancer discovery.

[28]  Jun S. Liu,et al.  Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR , 2015, Genome Biology.

[29]  J. Leitner,et al.  CD58/CD2 Is the Primary Costimulatory Pathway in Human CD28−CD8+ T Cells , 2015, The Journal of Immunology.

[30]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[31]  Steven A. Rosenberg,et al.  Adoptive immunotherapy for cancer: harnessing the T cell response , 2012, Nature Reviews Immunology.

[32]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[33]  Govind Bhagat,et al.  Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. , 2011, Cancer cell.

[34]  Po-Ling Loh,et al.  High-dimensional regression with noisy and missing data: Provable guarantees with non-convexity , 2011, NIPS.

[35]  M. Strioga,et al.  CD8+ CD28− and CD8+ CD57+ T cells and their role in health and disease , 2011, Immunology.

[36]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[37]  A. Kister,et al.  The CD58 (LFA-3) binding site is a localized and highly charged surface area on the AGFCC'C" face of the human CD2 adhesion domain. , 1993, Proceedings of the National Academy of Sciences of the United States of America.